Scarica l'app Stockscreener
26.74
0.04%
0.010
Precedente Chiudi:
$26.73
Aprire:
$26.87
Volume 24 ore:
285.40K
Relative Volume:
1.01
Capitalizzazione di mercato:
$1.76B
Reddito:
$282.04M
Utile/perdita netta:
$221.88M
Rapporto P/E:
7.9446
EPS:
3.3658
Flusso di cassa netto:
$-449.57M
1 W Prestazione:
+5.11%
1M Prestazione:
+12.21%
6M Prestazione:
+6.03%
1 anno Prestazione:
-30.85%
Intervallo 1D:
$26.66
$27.12
Intervallo di 1 settimana:
$26.29
$27.48
Portata 52W:
$22.36
$39.91
Galapagos Nv Adr Stock (GLPG) Company Profile
Nome
Galapagos Nv Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLPG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
26.74 | 1.76B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | Downgrade | Kepler | Hold → Reduce |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-11-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-04-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Iniziato | Maxim Group | Buy |
| 2020-10-21 | Downgrade | Goldman | Neutral → Sell |
| 2020-08-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-07-10 | Downgrade | Stifel | Buy → Hold |
| 2020-03-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Iniziato | BofA/Merrill | Neutral |
| 2019-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2019-07-31 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-29 | Downgrade | Jefferies | Buy → Hold |
Mostra tutto
Galapagos Nv Adr Borsa (GLPG) Ultime notizie
Galapagos To Spin Off Innovative Medicines Business - Forbes
Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
GalapagosAll Time High - Seeking Alpha
Galapagos Nv Adr Azioni (GLPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):